Search
rhIGFBP-3
go.drugbank.com/drugs/DB05897InvestigationalIt is developed by Insmed and is currently under phase I of the clinical trial.
SVV-001
go.drugbank.com/drugs/DB06129InvestigationalSVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional chemotherapeutics with no overt toxicity at doses one million times higher than effective doses in
Cirazoline
go.drugbank.com/drugs/DB09202ExperimentalCirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. … Cirazoline has also been shown to decrease food intake in rats, purportedly through activation of α1-adrenoceptors in the paraventricular nucleus in the hypothalamus of the brain.
Befunolol
go.drugbank.com/drugs/DB09013ExperimentalBefunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
MaxAdFVIII
go.drugbank.com/drugs/DB17713ExperimentalFirst developed by GenStar, it is being investigated for the treatment of hemophilia.
Mianserin
go.drugbank.com/drugs/DB06148ApprovedWithdrawnA tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of mirtazapine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTinoridine
go.drugbank.com/drugs/DB13001InvestigationalTinoridine is under investigation in clinical trial NCT01224756 (Efficacy of Tinoridine in Treating Pain and Inflammation in Adults).
Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalIprindole
go.drugbank.com/drugs/DB13496ExperimentalCategories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMelperone
go.drugbank.com/drugs/DB09224InvestigationalRecently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316]. … Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol.
MKC1106-PP
go.drugbank.com/drugs/DB06030ExperimentalMKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.).